Literature DB >> 6245099

Abnormal bone histology in idiopathic hypercalciuria.

H H Malluche, W Tschoepe, E Ritz, W Meyer-Sabellek, S G Massry.   

Abstract

Bone histology was evaluated in iliac creast biopsies of 15 patients with idiopathic hypercalciuria of the hyperabsorptive type and recurrent calcium oxalate stone formation. The biopsies were studied using quantitative histomorphometric analysis of undecalcified sections and fluorescent microscopy after double tetracycline labeling. Uring calcium and cAMP excretion were measured under basal conditions and after oral administration of calcium phosphate. Absorptive hypercalciuria was defined as a urinary excretion of calcium of more than 15 meq/24 h and/or a urinary ratio of Ca to Cr of more than 0.2, with a fall in the Ca to Cr ratio of more than 40% after the administration of oral cellulose phosphate. Osteoclastic bone resorption was normal or low in all patients and did not show any recognizable correlation with urinary calcium or urinary cAMP. All but one of the patients showed an increase in the fraction of inactive osteoid. Total osteoid was increased in 60% of the patients. Osteoblastic activity was significantly lower in the patient than in the control subjects. The fraction of mineralizing osteoid seams (i.e. seams with a tetracycline double labeling pattern), was diminished in all patients and the mean rate of apposition of bone matrix was decreased. These findings point to a diminished amount of bone matrix produced by individual osteoblasts and to a delay or cessation of terminal (secondary) mineralization of osteoid seams.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6245099     DOI: 10.1210/jcem-50-4-654

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  Impaired bone formation in male idiopathic osteoporosis: further reduction in the presence of concomitant hypercalciuria.

Authors:  J E Zerwekh; K Sakhaee; N A Breslau; F Gottschalk; C Y Pak
Journal:  Osteoporos Int       Date:  1992-05       Impact factor: 4.507

Review 2.  Bone disease and idiopathic hypercalciuria.

Authors:  Joseph E Zerwekh
Journal:  Semin Nephrol       Date:  2008-03       Impact factor: 5.299

Review 3.  Bone disease and hypercalciuria in children.

Authors:  Joseph E Zerwekh
Journal:  Pediatr Nephrol       Date:  2009-11-03       Impact factor: 3.714

4.  Involvement of low-calcium diet in the reduced bone mineral content of idiopathic renal stone formers.

Authors:  M Fuss; T Pepersack; J Van Geel; J Corvilain; J C Vandewalle; P Bergmann; J Simon
Journal:  Calcif Tissue Int       Date:  1990-01       Impact factor: 4.333

Review 5.  Bone disease in pediatric idiopathic hypercalciuria.

Authors:  Maria Goretti Moreira Guimarães Penido; Marcelo de Sousa Tavares
Journal:  World J Nephrol       Date:  2012-04-06

6.  Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers.

Authors:  Viviane Barcellos Menon; Rosa Maria Affonso Moysés; Samirah Abreu Gomes; Aluizio Barbosa de Carvalho; Vanda Jorgetti; Ita Pfeferman Heilberg
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-24       Impact factor: 8.237

Review 7.  Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

Authors:  Khashayar Sakhaee; Naim M Maalouf; Rajiv Kumar; Andreas Pasch; Orson W Moe
Journal:  Kidney Int       Date:  2010-12-01       Impact factor: 10.612

8.  Evaluation of cortical bone mass, thickness and density by z-scores in osteopenic conditions and in relation to menopause and estrogen treatment.

Authors:  S Meema; H E Meema
Journal:  Skeletal Radiol       Date:  1982       Impact factor: 2.199

Review 9.  Bone mineral content in calcium renal stone formers.

Authors:  A Trinchieri
Journal:  Urol Res       Date:  2005-08-03

10.  Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.

Authors:  R M Harrell; K W Lyles; J M Harrelson; N E Friedman; M K Drezner
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.